LEO PHARMA A/S: Financial statements 2018
CVR: 56759514
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 10,410,000,000 and a net result of DKK 1,258,000,000 compared with DKK 1,381,000,000 the year before. That is a decrease of 0.7% compared with the year before. The profit margin was 12.1%. Equity in the 2018 report amounted to DKK 9,528,000,000. The solvency ratio was 58.5%.
- Revenue
- DKK 10,410,000,000
- Gross Profit
- DKK 7,370,000,000
- Profit/Loss
- DKK 1,258,000,000
- Equity
- DKK 9,528,000,000
- Total Assets
- DKK 16,284,000,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 10.4 mia. | 7.4 mia. | 1.3 mia. | 9.5 mia. | - |
| 2017 | 10.5 mia. | 7.5 mia. | 1.4 mia. | 8.3 mia. | - |
| 2016 | 7.4 mia. | 2.7 mia. | 743 mio. | 25.2 mia. | 5170 |
| 2015 | 6.9 mia. | 2 mia. | 645 mio. | 25.3 mia. | 4813 |
| 2014 | 6.6 mia. | - | 1.5 mia. | 24.5 mia. | 4712 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of August 27, 2018, Patrik Olof Dahlén has joined the board of directors of LEO PHARMA A/S.
As of August 27, 2018, Olivier Bohuon has joined the board of directors of LEO PHARMA A/S.
As of August 26, 2018, Patrik Olof Dahlén has left the board of directors of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2017. Revenue came to DKK 10,481,000,000, and the net result was DKK 1,381,000,000.
As of February 27, 2018, Signe Maria Christensen has joined the board of directors of LEO PHARMA A/S.
As of February 27, 2018, Henrik Bo Andersson has joined the board of directors of LEO PHARMA A/S.
As of February 27, 2018, Jesper Mailind has joined the board of directors of LEO PHARMA A/S.
As of February 27, 2018, Franck Maréno has joined the board of directors of LEO PHARMA A/S.
As of February 27, 2018, Fie Falck Bruus Madsen has joined the board of directors of LEO PHARMA A/S.
As of February 27, 2018, Sammy Islam Al-Moalem has joined the board of directors of LEO PHARMA A/S.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.